⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iii cutaneous melanoma ajcc v7

Every month we try and update this database with for stage iii cutaneous melanoma ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02097225
BRAF V600E Muta...
BRAF V600K Muta...
Metastatic Mali...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable So...
Dabrafenib
Laboratory Biom...
Onalespib
Pharmacological...
Trametinib
18 Years - National Cancer Institute (NCI)
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaNCT02910700
Metastatic Mali...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Binimetinib
Dabrafenib
Encorafenib
Laboratory Biom...
Nivolumab
Pharmacological...
Trametinib
18 Years - M.D. Anderson Cancer Center
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by SurgeryNCT03325101
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Cryosurgery
Pembrolizumab
Pheresis
Therapeutic Aut...
18 Years - Mayo Clinic
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaNCT02965716
Advanced Melano...
Recurrent Melan...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Pembrolizumab
Talimogene Lahe...
18 Years - National Cancer Institute (NCI)
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by SurgeryNCT03325101
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Cryosurgery
Pembrolizumab
Pheresis
Therapeutic Aut...
18 Years - Mayo Clinic
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryNCT03021460
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Ibrutinib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaNCT02339571
Stage III Cutan...
Stage IV Cutane...
Biospecimen Col...
Computed Tomogr...
Echocardiograph...
Ipilimumab
Magnetic Resona...
Multigated Acqu...
Nivolumab
Sargramostim
18 Years - National Cancer Institute (NCI)
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic MelanomaNCT01807182
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Metastatic Mela...
Aldesleukin
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Therapeutic Tum...
18 Years - Fred Hutchinson Cancer Center
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryNCT01940809
BRAF V600E Muta...
BRAF V600K Muta...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Dabrafenib
Ipilimumab
Laboratory Biom...
Nivolumab
Trametinib
18 Years - National Cancer Institute (NCI)
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02097225
BRAF V600E Muta...
BRAF V600K Muta...
Metastatic Mali...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable So...
Dabrafenib
Laboratory Biom...
Onalespib
Pharmacological...
Trametinib
18 Years - National Cancer Institute (NCI)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryNCT01134614
Advanced Melano...
Metastatic Mela...
Recurrent Melan...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Ipilimumab
Sargramostim
18 Years - National Cancer Institute (NCI)
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by SurgeryNCT03325101
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Cryosurgery
Pembrolizumab
Pheresis
Therapeutic Aut...
18 Years - Mayo Clinic
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaNCT02965716
Advanced Melano...
Recurrent Melan...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Pembrolizumab
Talimogene Lahe...
18 Years - National Cancer Institute (NCI)
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic MelanomaNCT01740557
Metastatic Mela...
Stage III Cutan...
Stage IV Cutane...
Aldesleukin
CXCR2-transduce...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
NGFR-transduced...
Quality-of-Life...
18 Years - M.D. Anderson Cancer Center
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryNCT01134614
Advanced Melano...
Metastatic Mela...
Recurrent Melan...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Ipilimumab
Sargramostim
18 Years - National Cancer Institute (NCI)
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerNCT01480154
Advanced Malign...
Stage III Cutan...
Stage III Prost...
Stage III Renal...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Stage IV Prosta...
Stage IV Renal ...
Akt Inhibitor M...
Hydroxychloroqu...
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: